Identify new drug candidates, by accessing and evaluating registered drugs, pre-clinical and clinical candidates, focused sets and libraries with known anthelminthic activity from animal and human health companies
current phase of drug development
updated 29 Feb 2020
DNDi’s filarial disease programme actively identifies potential new drug candidates for onchocerciasis by evaluating registered drugs, as well as pre-clinical and clinical drug candidates. DNDi also investigates diverse chemical compounds against filarial worms.
Get our latest news, personal stories, research articles, and job opportunities.